History

Jan.

PharmAbcine announces a research collaboration with LegoChem Biosciences

Dec.

◦ PharmAbcine to present new interim data from its ongoing mTNBC trial at SABCS 2020


◦ Certification of Excellent Corporation R&D Center(ECRC)


Nov.

◦ PharmAbcine to present the final data of Phase IIa rGBM trial at SNO 2020


Sep.

◦ PharmAbcine Unveils Olinvacimab's Positive Results from Phase Ib Combination Studies at KSMO 2020


◦ PMC-403 and PMC-309 wins Poster Award at Korean Society of Medical Oncology(KSMO) 2020


Aug.

◦ PharmAbcine announces the execution of a Material Cooperative Research and Development Agreement (MCRADA) with the NIH to evaluate the efficacy of PMC-403 to treat SCLS


◦ PharmAbcine expands partnership with Samsung Biologics for PMC-403



◦ PharmAbcine signs a research collaboration agreement with Wuxi Shuangliang Biotechnology(SLBio) to evaluate a combination therapy to treat NSCLC


Jun.

◦ PharmAbcine Signs Long-term Contract Manufacturing Organization Agreement for Olinvacimab with Binex


◦ PharmAbcine enters into a development and manufacturing partnership with Thermo Fisher for PMC-309


Apr. 

◦ PharmAbcine signs a license agreement with Wincal Biopharm to expand indications of PharmAbcine's existing assets to non-oncology areas


◦ Samsung Biologics enters into a development and manufacturing partnership with PharmAbcine for oncology and neovascular treatment


Jan. 

◦ Company incorporation in the U.S


Nov.

◦ FPFV(First Patient Fist Visit) of phase 2 study of Olinvacimab treatment for rGBM patients who have progressed after bevacizumab treatment


Sep.

◦ FPFV(First Patient Fist Visit) of phase 2 study of Olinvacimab treatment for rGBM patients who have progressed after bevacizumab treatment


Aug. 

◦ Approval US IRB(Stanford Hospital) of Olinvacimab phase 2 study for the treatment of rGBM patient who has progressed after bevacizumab treatment


◦ Approval Australia HREC of Olinvacimab phase 2 study for the treatment of rGBM patient who has progressed after bevacizumab treatment


May.

◦ Issuance of CB(KRW 100 Billion)


◦ PharmAbcine enters into a development and manufacturing partnership with Thermo Fisher for PMC-309


Jan.

◦ FPFV(First patient First visit) on the study of Olinvacimab/Pembrolizumab combination trial for the treatment of rGBM patients


◦ FPFV(First patient First visit) on the study of Olinvacimab/Pembrolizumab combination trial for the treatment of mTNBC patients

Dec.

◦ Olinvacimab + Keytruda combo phase 1b/2 for both recurrent Glioblastoma multiforme and metastatic Triple Negative Breast Cancer trials are open to recruit patients at multicenter in Australia


Nov.

◦ November 21, 2018 / KOSDAQ listed


◦ Company incorporation in Australia


Oct.

◦ Orphan drug development appointed


Sep.

◦ Approval of Olinvacimab Phase II IND for Avastine refractory rGBM Patients


◦ Biologics Award


Mar. 

◦ ODD approval of Olinvacimab for rGBM


Jan.

◦ Clinical Research Collaboration for Combo Trials



Jun.

◦ Completion of Olinvacimab Phase IIa for rGBM Patients


Apr.

◦ Commendation from KHIDI


Jun.

◦ Commendation from KFDS


Feb.

◦ Start of Olinvacimab Phase IIa for rGBM Patients




Oct.

◦ Olinvacimab Achieved an excellence in national R&D Selected for 100 selections as the best accomplishments Awarded from Ministry of Science and ICT


Sep.

◦ Nominated as Korea Brain Power Company in 2015


Dec.

◦ Out-Licensing PMC-001


◦ Health and Medical Technology Development Business Award(CEO)


Nov.

◦ Award from the Minister from KMTIE

- Distinguished Industrial Engineer(CEO)

- Technology Commercialization(CFO)


Oct. 

◦ Out-Licensing of Olinvacimab


Jul.

◦ Out-Licensing of PMC-001


Jun.

◦ Tech-Connect National Innovation Award


May.

◦ Korea Eureka Day Award 2014


Mar.

◦ Out-Licensing of Olinvacimab


◦ Selected as INNOBIZ company


Oct.

◦ Ministry of Education Award


Sep.

◦ Completion of Olinvacimab Phase 1


Mar.

◦ Out-Licensed of 1E4 mAb

Nov.

◦ Research collaboration with Sanofi-Aventis


Apr.

◦ Pharma -Idol Award from 7th Annual China Pharmaceutical R&D Summit Conference


Nov.

◦ Start of Olinvacimab (TTAC-0001, formerly known as tanibirumab) Phase 1


Sep.

◦ Green Technology Citification


Jul.

◦ Olinvacimab (TTAC-0001, formerly known as

tanibirumab) IND approved

Dec.

◦ R&D Center affiliated


Sep.

◦ Designation of foreign investment company


Mar.

◦ Certificated as venture business

Oct.

◦ Grand Prix from 1st GATE Project


Sep.

◦ September 9, 2008 / Foundation of PharmAbcine Inc.



LinkedIn  I   Facebook  I  YouTube



    • 2F, Research Building 2, 70, Yuseong-daero 1689 beon-gil,
      Yuseong-gu, Daejeon, 34047, Republic of Korea
    • HQ +82-42-863-2017
    • R&D Center +82-42-861-2017
    • FAX +82-42-863-2080
  • COPYRIGHT BY PharmAbcine Inc. ALL RIGHTS RESERVED.